{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-003854","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.581381+00:00","generated_at":"2026-05-19T12:01:44.975853+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aptose reports safety, CRs, MRD negativity in TUSCANY triplet for newly diagnosed AML","bullets":["Ten newly diagnosed AML patients dosed in TUS+VEN+AZA triplet at 40, 80, 120 mg TUS; no DLTs observed.","At 40 mg, 3 of 4 patients achieved CRs and MRD negativity, including FLT3-ITD, FLT3-WT, and TP53/CK.","At 80 mg, all 3 patients achieved composite CRs (CR/CRi); one TP53-mutated/CK patient had early CRi.","No treatment-related deaths; all 10 subjects remain alive; no prolonged myelosuppression or QT prolongation.","Data presented at EHA 2025; TUS+VEN+AZA well-tolerated with standard of care dosing; enrollment ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-003854","json":"https://secwatch.observer/filing/0001171843-25-003854.json","markdown":"https://secwatch.observer/filing/0001171843-25-003854.md","text":"https://secwatch.observer/filing/0001171843-25-003854.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325003854/0001171843-25-003854-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325003854/f8k_061125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T12:01:44.975853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}